Emcure Pharma IPO Description – Emcure Pharmaceuticals stands as a prominent Indian pharmaceutical entity, dedicated to the advancement, production, and global promotion of an extensive array of pharmaceutical products spanning various critical therapeutic domains. Functioning as a research and development (R&D) oriented enterprise, Emcure boasts a distinct product portfolio encompassing oral medications, injectables, and biotherapeutics. This diverse range has facilitated its market penetration into over 70 countries, establishing a robust presence in India, Europe, and Canada.
Emcure Pharmaceuticals secured notable rankings in the pharmaceutical landscape, clinching the 13th position among the largest pharmaceutical companies in India based on Domestic Sales for MAT September 2023. Additionally, it proudly held the 4th spot in terms of market share in its Covered Markets for the same period. Notably, Emcure emerged as the foremost pharmaceutical company in India for Domestic Sales in the therapeutic areas of gynecology and human immunodeficiency virus (HIV) antivirals for MAT September 2023.
Emcure Pharmaceuticals has 13 manufacturing facilities across India. The company has witnessed substantial sales expansion in India over the recent years. Its sales in India accounted for 50.84% and 53.16% of the total revenue from operations during the six months ended 30 September 2023, and the entire FY 2023, respectively.
The competitive edge of the company in the domestic market arises from its distinctive product portfolio. This uniqueness has enabled the company to establish a strong presence in numerous critical therapeutic areas, encompassing gynecology, cardiovascular health, vitamins, minerals, nutrients, HIV antivirals, blood-related disorders, and oncology/anti-neoplastic. Across all such therapeutic areas, it is ranked among the top 10 pharmaceutical companies in India in terms of domestic sales in India in September 2023.
Promoters of Emcure Pharma – Satish Ramanlal Mehta, and Sunil Rajanikant Mehta
Emcure Pharma IPO Details
| Emcure Pharma IPO Dates | Coming soon |
| Emcure Pharma Issue Price | Coming soon |
| Fresh issue | INR 800 crore |
| Offer For Sale | 13,678,839 shares |
| Total IPO size | Coming soon |
| Minimum bid (lot size) | Coming soon |
| Face Value | INR 10 per share |
| Retail Allocation | 35% |
| Listing On | BSE, NSE |
Emcure Pharma’s Financial Performance
| FY 2021 | FY 2022 | FY 2023 | H1 FY 2024 | |
| Revenue | 5,033.47 | 5,855.39 | 5,985.81 | 3,219.25 |
| Expenses | 4,222.13 | 4,946.31 | 5,278.36 | 2,843.06 |
| Net income | 418.59 | 702.56 | 561.85 | 286.80 |
| Margin (%) | 8.32 | 12.00 | 9.39 | 8.91 |
Emcure Pharma IPO News
- Emcure Pharma IPO RHP
- Emcure Pharma IPO DRHP
- ASBA IPO Forms
- Live IPO Subscription Status
- IPO Subscription Status
Emcure Pharma Valuations & Margins
| FY 2021 | FY 2022 | FY 2023 | |
| EPS | 21.68 | 36.62 | 29.42 |
| PE ratio | – | – | – |
| RONW (%) | 17.25 | 33.32 | 21.27 |
| NAV | 125.68 | 109.90 | 138.30 |
| ROCE (%) | 20.58 | 29.69 | 22.01 |
| EBITDA (%) | 19.35 | 23.54 | 20.24 |
| Debt/Equity | – | – | – |
Emcure Pharma IPO GMP Today (Daily Trend)
| Date | Day-wise IPO GMP | Kostak | Subject to Sauda |
| Coming soon | – | – | – |
Emcure Pharma IPO Objectives
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the company
- General corporate purposes
Emcure Pharma IPO Subscription – Live Updates
Coming soon
Emcure Pharma – Comparison With Listed Peers
| Company | Face Value | PE ratio | EPS | RONW (%) | NAV | Revenue (Cr.) |
| Emcure Pharmaceuticals | 10 | – | 29.42 | 21.27 | 138.30 | 5,985.81 |
| Dr. Reddy’s Laboratories | 5 | 20.45 | 270.90 | 19.36 | 1,398.33 | 24,669.70 |
| Cipla Limited | 2 | 34.55 | 34.69 | 11.97 | 290.01 | 22,753.12 |
| Alkem Laboratories | 2 | 58.25 | 82.31 | 10.88 | 756.52 | 11,599.26 |
| Torrent Pharmaceuticals | 5 | 55.66 | 36.79 | 20.09 | 183.13 | 9,620.15 |
| Mankind Pharma | 1 | 57.80 | 32.00 | 17.24 | 185.61 | 8,749.43 |
| Abbott India | 10 | 51.10 | 446.78 | 29.78 | 1,500.54 | 5,348.73 |
| J. B. Chemicals & Pharmaceuticals | 2 | 55.72 | 26.17 | 16.52 | 320.55 | 3,149.28 |
Emcure Pharma IPO Allotment Status
Emcure Pharma IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.
Emcure Pharma IPO Dates & Listing Performance
| Emcure Pharma IPO Opening Date | Coming soon |
| Emcure Pharma IPO Closing Date | Coming soon |
| Finalisation of Basis of Allotment | Coming soon |
| Initiation of refunds | Coming soon |
| Transfer of shares to demat accounts | Coming soon |
| Emcure Pharma IPO Listing Date | Coming soon |
| Opening Price on NSE | Coming soon |
| Closing Price on NSE | Coming soon |
Emcure Pharma IPO Reviews – Subscribe or Avoid?
Angel One –
Anand Rathi –
Axis Capital –
Antique Stock Broking –
Arihant Capital –
Ashika Research –
Asit C Mehta –
BP Wealth –
Capital Market –
Canara Bank Securities –
Choice Broking –
Dalal & Broacha –
Elite Wealth –
GCL Broking –
Geojit –
GEPL Capital –
Hem Securities –
ICICIdirect –
Investmentz –
Jainam Broking –
DR Choksey –
LKP Research –
Marwadi Financial –
Motilal Oswal –
Nirmal Bang –
Reliance Securities –
Religare Broking –
Samco Securities –
SMC Global –
Swastika Investmart –
Ventura Securities –
Emcure Pharma Offer Lead Manager
KOTAK MAHINDRA CAPITAL COMPANY LIMITED
27 BKC, 1st Floor, Plot no. C-27,
‘G’ Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051
Phone: +91 22 4336 0000
Email: [email protected]
Website: www.investmentbank.kotak.com
Emcure Pharma Offer Registrar
Link Intime India Private Limited
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West), Mumbai 400 083, Maharashtra, India
Phone: +91 810 811 4949
Email: [email protected]
Website: www.linkintime.co.in
Emcure Pharma Contact Details
EMCURE PHARMACEUTICALS LIMITED
Plot No. P-1 and P-2, IT-BT Park, Phase II,
M.I.D.C., Hinjawadi, Pune 411 057, Maharashtra
Phone: +91 20 3507 0033, +91 20 3507 0000
Email: [email protected]
Website: www.emcure.com
Emcure Pharma IPO FAQs
How many shares in Emcure Pharma IPO are reserved for HNIs and retail investors?
The investors’ portion for QIB – 50%, NII – 15%, and Retail – 35%.
How to apply in Emcure Public Offer?
The best way to apply in Emcure public offer is through Internet banking ASBA (know all about ASBA here). You can also apply online through your stock broker using UPI. If you prefer to make paper applications, fill up an offline IPO form and deposit the same to your broker.
What is Emcure Pharma IPO GMP today?
Emcure Pharma IPO GMP today is NA per share.
What is Emcure IPO kostak rate today?
Emcure IPO kostak rate today is NA per application.
What is Emcure Pharma Subject to Sauda rate today?
Emcure Pharma Subject to Sauda rate today is NA per application.
